DOI: https://doi.org/10.14710/genres.v5i2.25626

Evaluasi Rasionalitas Penggunaan Obat Golongan Penyekat Beta Pada Pasien Gagal Jantung di Rumah Sakit Daerah K.R.M.T Wongsonegoro Semarang

*Intan Rahmania Eka Dini orcid  -  Universitas Diponegoro, Indonesia
Eva Annisaa orcid  -  Universitas Diponegoro, Indonesia
Adella Ghalda Safira  -  Universitas Diponegoro, Indonesia
Received: 3 Jan 2025; Revised: 7 Jan 2025; Accepted: 20 Jun 2025; Available online: 15 Jul 2025; Published: 15 Jul 2025.
Open Access Copyright 2025 Generics: Journal of Research in Pharmacy

Creative Commons License
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.

Citation Format:
Abstract
Gagal jantung merupakan salah satu penyakit kardiovaskuler yang ditandai dengan kegagalan memompa darah dan oksigen keseluruh tubuh. Salah satu terapi yang digunakan pada gagal jantung adalah antihipertensi, yaitu golongan penyekat beta. Ketidakrasionalan penggunaan penyekat beta akan menimbulkan berbagai macam terjadinya efek obat yang tidak diinginkan serta ketidaktercapaian target terapi. Penelitian ini bertujuan melakukan evaluasi rasionalitas penggunaan obat penyekat beta untuk memberikan gambaran penggunaan penyekat beta umumnya dan memberikan masukan untuk perbaikan penggunaan obat dimasa yang akan datang. Penelitian dilakukan di Rumah Sakit Daerah K.R.M.T Wongsonegoro Kota Semarang dengan rancangan penelitian cohort retrospektif. Sampel merupakan pasien gagal jantung rawat jalan yang menggunakan obat penyekat beta dan diambil dengan metode simple random sampling. Hasil penelitian menunjukkan 91% pasien gagal jantung di Rumah Sakit Daerah K.R.M.T Wongsonegoro tahun 2022 menggunakan obat golongan penyekat beta secara rasional.
Fulltext View|Download
Keywords: Beta Blocker, Gagal Jantung, Evaluasi Pengobatan, Fraksi Ejeksi

Article Metrics:

Article Info
Section: Articles
Language : ID
Recent articles
Evaluasi Rasionalitas Penggunaan Obat Golongan Penyekat Beta Pada Pasien Gagal Jantung di Rumah Sakit Daerah K.R.M.T Wongsonegoro Semarang Identifikasi Kejadian Ikutan Pasca Imunisasi (KIPI) Vaksin COVID-19 pada Karyawan Apotekku Group Wilayah Bali Periode Februari-Maret Tahun 2023 Pengaruh Pemberian Ekstrak Etanol Daun Bakau Rhizophora mucronata terhadap Pertumbuhan Jamur Candida albicans More recent articles
  1. Alhumaidi, R. M., Al-Ali, A. Y., Al-Rashidi, M. N., Al-Mutairi, A. H., & Al-Abdulkareem, A. (2023). Risk of polypharmacy and its outcome in terms of drug interaction in an elderly population: A retrospective cross-sectional study. Journal of Clinical Medicine, 12(12). https://doi.org/10.3390/jcm12123960
  2. Choi, K. H., Lee, J. M., Youn, T. J., et al. (2019). The mortality benefit of carvedilol versus bisoprolol in patients with heart failure with reduced ejection fraction. Korean Journal of Internal Medicine, 34(5), 1030–1039. https://doi.org/10.3904/kjim.2018.009
  3. Eriksson, B., Andersson, M., & Nilsson, G. (2024). A higher mortality in men compared to women with heart failure in primary care and ejection fraction equal to or more than 40%. Critical Public Health, 34(1), 1–13. https://doi.org/10.1080/09581596.2024.2421966
  4. Groenewegen, A., Rutten, F. H., Mosterd, A., & Hoes, A. W. (2020). Epidemiology of heart failure. European Journal of Heart Failure, 22, 1342–1356. https://doi.org/10.1002/ejhf.1858
  5. Harigustian, Y., Dewi, A., & Khoiriyati, A. (2016). Gambaran karakteristik pasien gagal jantung usia 45–65 tahun di RS PKU Muhammadiyah Gamping. Indonesian Journal of Nursing Practices, 1(1), 55–60. https://doi.org/10.18196/ijnp.1152
  6. Heidenreich, P. A., Bozkurt, B., Aguilar, D., et al. (2022). 2022 AHA/ACC/HFSA Guideline for the management of heart failure: A report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation, 145, E895–E1032. https://doi.org/10.1161/CIR.0000000000001063
  7. Istiani, A., & Lolita. (2019). Evaluasi kerasionalan dan kuantitas penggunaan antihipertensi pada pasien gagal jantung di instalasi rawat inap Rumah Sakit PKU Muhammadiyah Gamping Yogyakarta. Jurnal Ilmiah Farmasi, 15(1), 37–50. http://journal.uii.ac.id/index.php/JIF
  8. Kawabata, M., Oka, T., & Kawahara, T. (2015). Severe iatrogenic bradycardia related to the combined use of beta-blocking agents and sodium channel blockers. Clinical Pharmacology: Advances and Applications, 7, 29–36. https://doi.org/10.2147/CPAA.S77021
  9. Kementerian Kesehatan RI. (2021). Pedoman Nasional Pelayanan Kedokteran Tata Laksana Gagal Jantung
  10. Ko, D. T., Mamdani, M., Alter, D. A., et al. (2004). Adverse effects of beta-blocker therapy for patients with heart failure: A quantitative overview of randomized trials. Tersedia di: www.fda.gov
  11. Macdonald, P. S., Keogh, A. M., Aboyoun, C. L., et al. (1999). Tolerability and efficacy of carvedilol in patients with New York Heart Association Class IV heart failure. Generics: Journal of Research in Pharmacy, 5(2), 20
  12. Murphy, S. P., Ibrahim, N. E., & Januzzi, J. L. (2020). Heart failure with reduced ejection fraction: A review. JAMA: Journal of the American Medical Association, 324(5), 488–504. https://doi.org/10.1001/jama.2020.10262
  13. Ponikowski, P., Voors, A. A., Anker, S. D., et al. (2016). 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal, 37(27), 2129–2200. https://doi.org/10.1093/eurheartj/ehw128
  14. Ramadhian. (2013). Faktor-faktor yang berhubungan dengan kejadian congestive heart failure di RSU Palembang Mohammad Hoesin 2011
  15. Regitz-Zagrosek, V. (2020). Sex and gender differences in heart failure. International Journal of Heart Failure, 2(3), 157–181. https://doi.org/10.36628/ijhf.2020.0004
  16. Severino, P., D'Amato, A., Pucci, M., et al. (2020). Ischemic heart disease and heart failure: Role of coronary ion channels. International Journal of Molecular Sciences, 21(9), 3167. https://doi.org/10.3390/ijms21093167
  17. Sponer, G., Posival, H., & Kloiber, R. (1992). Vasodilatory action of carvedilol. Journal of Cardiovascular Pharmacology, 19(Suppl 1), S5–S11. https://doi.org/10.1097/00005344-199219001-00003
  18. Strauss, M. H., Hall, A. S., & Narkiewicz, K. (2023). The combination of beta-blockers and ACE inhibitors across the spectrum of cardiovascular diseases. Cardiovascular Drugs and Therapy, 37(5), 757–770. https://doi.org/10.1007/s10557-021-07248-1
  19. Tucker, W. D., Sankar, P., & Theetha Kariyanna, P. (2025). Selective beta-1 blockers
  20. Vedin, O., Lam, C. S. P., Koh, A. S., et al. (2017). Significance of ischemic heart disease in patients with heart failure and preserved, midrange, and reduced ejection fraction: A nationwide cohort study. Circulation: Heart Failure, 10(6). https://doi.org/10.1161/CIRCHEARTFAILURE.117.003875
  21. Zheng, H. (2025). Distinguishing between mortality rates for heart failure with preserved versus reduced ejection fraction. The Lancet Global Health, 13(1), e26. https://doi.org/10.1016/S2214-109X(24)00448-0

Last update:

No citation recorded.

Last update:

No citation recorded.